AI adoption is not failing because of missing tools. It is failing at the decision layer.
Pharma and biotech SMEs face enormous pressure to adopt AI, but teams struggle to know which use cases are relevant, feasible, compliant, and economically valuable.
Fragmented AI Landscape
Hundreds of vendors, papers, consultants, and generic AI tools compete for attention. There is no structured way to identify what is actually relevant for a specific organization.
Compliance & Trust Concerns
Regulated industries face strict data governance, privacy, and validation requirements. Generic AI tools offer no compliance guidance, creating real adoption risk.
Limited Internal Capacity
Most pharma and biotech SMEs lack dedicated AI strategy teams. Employees from operations to C-level must navigate complex AI decisions without structured support.
Expensive, Non-Scalable Consulting
Traditional AI consulting is costly, slow, and hard to scale. Bespoke engagements deliver point-in-time recommendations that become outdated quickly.
Many companies are interested in AI, but still rely on trial and error because they lack trusted, context-specific guidance.